Outcome Documents of the Science Board

The Fourth Term (-March, 2020) Subcommittees

• Report on Clinical Evaluation of Antimicrobial Agents for AMR

 

The Third Term (-March, 2018) Subcommittees

• Current state of therapeutic development for rare cancers in Japan, and proposals for improvement(Cancer Sci., 109(5):1731-1737, May 2018)

 

• Issues in and Proposals for Facilitating Drug Discovery by Collaboration between Academia and Industry2017 - In the Trend of Rapidly Advancing Science -

 

• Regulatory Science on AI-based Medical Devices and Systems(Adv Biomed Eng., 7: 118-123, 2018)

 

The Second Term (-March, 2016) Subcommittees

• Report on the Use of Numerical Analysis for Strength Evaluation of Orthopedic Implants

 

• Current Status and Perspectives of Placebo-controlled Studies

 

• Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs(Cancer Sci., 107(2):189-202, February 2016)

 

• Discussions on Evaluation of Medical Devices in Pediatric Use

 

• Proposal on Basic Principle to Quality Assurance of Cell Therapy (CT) Products

 

The First Term (-March, 2014) Subcommittees

• Current Perspective on Evaluation of Tumorigenicity of Cellular and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials


• Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs


• Summary of discussion on the assessment of the current status of personalized medicine related to development and regulatory review